Mosanna Therapeutics' first goal is to bring an effective and well-tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea (MOSA) patients.
Mosanna Therapeutics has raised €70M across 2 funding rounds from 6 investors, most recently a Series A round in Jun 2025. Based in Zurich, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2025-06-10 | Series A | €70M | Broadview Ventures,EQT Life Sciences,Forbion,Norwest,Pivotal bioVenture Partners | View deal → |
| 2022-07-15 | Seed | — | Forty51 Ventures | View deal → |
